Availability of Medicines for the Population as a Determinant of the Sustainable Development of the National Health System

The purpose of the study was to analyse the availability of medicines for the population on the example of the treatment of cardiovascular diseases in 2011 and 2019 to assess the assortment, financial and logistical availability of medicines as a determinant of the sustainable development of the national health system. A comparative and structural analysis of the availability of medicines for the treatment of diseases of the cardiovascular system was carried out according to the monitoring of the assortment and prices of vital and essential medicines in the Sverdlovsk Region for 2011 and 2019, including using the WHO’s methodology and the International Non-governmental organization "Action Program for Health and Healthcare". The availability and prices of 274 medicines’ trade names in the hospital and outpatient segments of the Sverdlovsk region revealed and the direct costs of patients for purchasing medicines for arterial hypertension treatment in 2019 estimated. As a result, of the study, according to data from 2011 and from 2019, in general, there was a decrease in prices relative to reference prices for generic drugs for the treatment of cardiovascular diseases. To increase the effectiveness of drug provision as a determinant of the sustainable development of the national health system, additional studies of price dynamics and pharmacoeconomical analysis needed, taking into account trends in the Russian pharmaceutical market.